United States Influenza Vaccine Market, Vaccination Analysis, Distribution, Production, Pipeline Insights, Clinical Trials, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast,2016 to 2022
United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market.
Major and Promising Vaccine covered in the report are as follows:
1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4. Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8. FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax
Key Companies Covered in the Report are as follows
1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZenecca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market.
Major and Promising Vaccine covered in the report are as follows:
1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4. Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8. FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax
Key Companies Covered in the Report are as follows
1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZenecca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate
1. EXECUTIVE SUMMARY
2. UNITED STATES INFLUENZA VACCINE MARKET & FORECAST
3. UNITED STATES NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINE
3.1 Number of Children Vaccinated
3.2 Number of Adults Vaccinated
4. UNITED STATES INFLUENZA VACCINE MARKET DRIVERS AND BARRIERS
4.1 Market Drivers
4.2 Market Barriers
5. UNITED STATES INFLUENZA VACCINE PRODUCTION & DISTRIBUTION
5.1 Vaccine Choices Remain Available for Patients, Providers
5.2 Influenza Vaccine Price Trends
5.2.1 Pediatric Influenza Vaccine Price Trends
5.2.2 Adult Influenza Vaccine Price Trends
5.3 Influenza Vaccine Production, Supply, and Allocation
5.4 Influenza Vaccine Distribution & Demand
5.5 Influenza Vaccine Effectiveness
5.6 Managing Influenza with Diagnostic Resources
5.7 Distribution Method of Influenza Vaccination
6. UNITED STATES INFLUENZA VACCINE MARKET – REGULATORY LANDSCAPE
7. MARKET DYNAMICS – MERGERS, ACQUISITIONS, KEY AGREEMENTS & COLLABORATIONS
7.1 Merger & Acquisitions
7.2 Collaboration Deal
7.3 Licensing, Exclusive & Distribution Agreement Deal
7.3.1 Licensing Agreement
7.3.2 Exclusive Agreement
7.3.3 Distribution Agreement
8. INFLUENZA VACCINE – PIPELINE ASSESSMENT
8.1 Promising Vaccine in Clinical Development
8.2 Promising Vaccine in Early–Stage Development
9. INFLUENZA VACCINE – CLINICAL TRIALS ASSESSMENT BY PHASE AND TRIAL STATUS
9.1 Year 2016
9.2 Year 2015
9.3 Year 2014
9.4 Year 2013
10. KEY COMPANIES ANALYSIS
10.1 Sanofi Pasteur
10.1.1 Business Overview
10.1.2 Sanofi Pasteur – Influenza Vaccine Outlook
10.1.2.1 Fluzone High–Dose Vaccine
10.1.2.2 Fluzone Quadrivalent Vaccine
10.1.2.3 Intradermal (ID) Trivalent Influenza Vaccine
10.1.2.4 Vaxigrip Vaccine
10.1.3 Influenza Vaccine Sales Analysis
10.2 GlaxoSmithKline (GSK)
10.2.1 GlaxoSmithKline(GSK) – Influenza Vaccine Outlook
10.2.1.1 Fluarix Quadrivalent
10.2.1.2 Flulaval Quadrivalent
10.2.2 Influenza Vaccine Sales Analysis & Forecast
10.3 AstraZeneca
10.3.1 Business Overview
10.3.2 AstraZeneca – Influenza Vaccine Outlook
10.3.2.1 Fluenz Tetra/FluMist Quadrivalent
10.3.3 Influenza Vaccine Sales Analysis
10.4 Protein Sciences Corporation
10.4.1 Business Overview
10.4.2 Protein Sciences Corporation – Influenza Vaccine Outlook
10.4.2.1 Flublok
10.5 Seqirus (CSL Limited)
10.5.1 Business Overview
10.5.2 Seqirus – Influenza Vaccine Outlook
10.5.2.1 Flucelvax Quadrivalent
10.5.2.2 Afluria Quadrivalent
10.5.2.3 Agrippal
10.5.2.4 Fluad
10.5.2.5 Fluvirin
10.5.2.6 Fluvax
2. UNITED STATES INFLUENZA VACCINE MARKET & FORECAST
3. UNITED STATES NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINE
3.1 Number of Children Vaccinated
3.2 Number of Adults Vaccinated
4. UNITED STATES INFLUENZA VACCINE MARKET DRIVERS AND BARRIERS
4.1 Market Drivers
4.2 Market Barriers
5. UNITED STATES INFLUENZA VACCINE PRODUCTION & DISTRIBUTION
5.1 Vaccine Choices Remain Available for Patients, Providers
5.2 Influenza Vaccine Price Trends
5.2.1 Pediatric Influenza Vaccine Price Trends
5.2.2 Adult Influenza Vaccine Price Trends
5.3 Influenza Vaccine Production, Supply, and Allocation
5.4 Influenza Vaccine Distribution & Demand
5.5 Influenza Vaccine Effectiveness
5.6 Managing Influenza with Diagnostic Resources
5.7 Distribution Method of Influenza Vaccination
6. UNITED STATES INFLUENZA VACCINE MARKET – REGULATORY LANDSCAPE
7. MARKET DYNAMICS – MERGERS, ACQUISITIONS, KEY AGREEMENTS & COLLABORATIONS
7.1 Merger & Acquisitions
7.2 Collaboration Deal
7.3 Licensing, Exclusive & Distribution Agreement Deal
7.3.1 Licensing Agreement
7.3.2 Exclusive Agreement
7.3.3 Distribution Agreement
8. INFLUENZA VACCINE – PIPELINE ASSESSMENT
8.1 Promising Vaccine in Clinical Development
8.2 Promising Vaccine in Early–Stage Development
9. INFLUENZA VACCINE – CLINICAL TRIALS ASSESSMENT BY PHASE AND TRIAL STATUS
9.1 Year 2016
9.2 Year 2015
9.3 Year 2014
9.4 Year 2013
10. KEY COMPANIES ANALYSIS
10.1 Sanofi Pasteur
10.1.1 Business Overview
10.1.2 Sanofi Pasteur – Influenza Vaccine Outlook
10.1.2.1 Fluzone High–Dose Vaccine
10.1.2.2 Fluzone Quadrivalent Vaccine
10.1.2.3 Intradermal (ID) Trivalent Influenza Vaccine
10.1.2.4 Vaxigrip Vaccine
10.1.3 Influenza Vaccine Sales Analysis
10.2 GlaxoSmithKline (GSK)
10.2.1 GlaxoSmithKline(GSK) – Influenza Vaccine Outlook
10.2.1.1 Fluarix Quadrivalent
10.2.1.2 Flulaval Quadrivalent
10.2.2 Influenza Vaccine Sales Analysis & Forecast
10.3 AstraZeneca
10.3.1 Business Overview
10.3.2 AstraZeneca – Influenza Vaccine Outlook
10.3.2.1 Fluenz Tetra/FluMist Quadrivalent
10.3.3 Influenza Vaccine Sales Analysis
10.4 Protein Sciences Corporation
10.4.1 Business Overview
10.4.2 Protein Sciences Corporation – Influenza Vaccine Outlook
10.4.2.1 Flublok
10.5 Seqirus (CSL Limited)
10.5.1 Business Overview
10.5.2 Seqirus – Influenza Vaccine Outlook
10.5.2.1 Flucelvax Quadrivalent
10.5.2.2 Afluria Quadrivalent
10.5.2.3 Agrippal
10.5.2.4 Fluad
10.5.2.5 Fluvirin
10.5.2.6 Fluvax
LIST OF TABLES
Table 5–1: United States Influenza Vaccine Available,2016 –
Table 5–2: United States – Pediatric Influenza Vaccine Price, 2016 – 2017
Table 5–3: United States – Adult Influenza Vaccine Price, 2016 – 2017
Table 5–4: United States – Flu Vaccine Production, Supply, and Allocation
Table 5–5: Total Percentage of Flu Vaccines Released by Week,2016 – 2017
Table 5–6: Total Percentage of Flu Vaccines Released by Week,2015 – 2016
Table 5–7: Total Percentage of Flu Vaccines Released by Week,2014 – 2015
Table 5–8: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2005 – 2016
Table 5–9: Managing Influenza with Diagnostic Resources
Table 5–10: Distribution of Influenza Vaccination
Table 6–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 7–1: Influenza Vaccine Market – Merger & Acquisitions (Million US$),2003 – 2015
Table 7–2: Influenza Vaccine Market – Collaborations Deal,2007 – 2016
Table 7–3: Influenza Vaccine Market – Licensing Agreement,2007 – 2016
Table 7–4: Influenza Vaccine Market – Exclusive Agreement,2009 – 2016
Table 7–5: Influenza Vaccine Market – Distribution Agreement,2005 – 2016
Table 5–1: United States Influenza Vaccine Available,2016 –
Table 5–2: United States – Pediatric Influenza Vaccine Price, 2016 – 2017
Table 5–3: United States – Adult Influenza Vaccine Price, 2016 – 2017
Table 5–4: United States – Flu Vaccine Production, Supply, and Allocation
Table 5–5: Total Percentage of Flu Vaccines Released by Week,2016 – 2017
Table 5–6: Total Percentage of Flu Vaccines Released by Week,2015 – 2016
Table 5–7: Total Percentage of Flu Vaccines Released by Week,2014 – 2015
Table 5–8: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2005 – 2016
Table 5–9: Managing Influenza with Diagnostic Resources
Table 5–10: Distribution of Influenza Vaccination
Table 6–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 7–1: Influenza Vaccine Market – Merger & Acquisitions (Million US$),2003 – 2015
Table 7–2: Influenza Vaccine Market – Collaborations Deal,2007 – 2016
Table 7–3: Influenza Vaccine Market – Licensing Agreement,2007 – 2016
Table 7–4: Influenza Vaccine Market – Exclusive Agreement,2009 – 2016
Table 7–5: Influenza Vaccine Market – Distribution Agreement,2005 – 2016
LIST OF FIGURES
Figure 2 1: United States – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 2 2: United States – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 3 1: United States – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 3 2: United States – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 3 3: United States – Number of Children Vaccinated(Thousand),2010 – 2015
Figure 3 4: United States – Forecast for Number of Children Vaccinated(Thousand),2016 – 2022
Figure 3 5: United States – Number of Adults Vaccinated(Thousand),2010 – 2015
Figure 3 6: United States – Forecast for Number of Adults Vaccinated(Thousand),2016 – 2022
Figure 5 1: United States – Influenza Vaccine Doses Distributed, By Season(Million),2010 – 2016
Figure 10 1: Sanofi Pasteur – Influenza Vaccine Net Sales (Million US$),2011 – 2015
Figure 10 2: Sanofi Pasteur – Forecast for Influenza Vaccine Net Sales (Million US$),2016 – 2022
Figure 10 3: GSK – Influenza Vaccine Net Sales (Million US$),2011 – 2015
Figure 10 4: GSK – Forecast for Influenza Vaccine Net Sales (Million US$),2016 – 2022
Figure 10 5: AstraZeneca – Influenza Vaccine Net Sales (Million US$),2011 – 2015
Figure 2 1: United States – Influenza Vaccine Market (Million US$),2010 – 2015
Figure 2 2: United States – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022
Figure 3 1: United States – Total Number of Persons Vaccinated(Thousand), 2010 – 2015
Figure 3 2: United States – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022
Figure 3 3: United States – Number of Children Vaccinated(Thousand),2010 – 2015
Figure 3 4: United States – Forecast for Number of Children Vaccinated(Thousand),2016 – 2022
Figure 3 5: United States – Number of Adults Vaccinated(Thousand),2010 – 2015
Figure 3 6: United States – Forecast for Number of Adults Vaccinated(Thousand),2016 – 2022
Figure 5 1: United States – Influenza Vaccine Doses Distributed, By Season(Million),2010 – 2016
Figure 10 1: Sanofi Pasteur – Influenza Vaccine Net Sales (Million US$),2011 – 2015
Figure 10 2: Sanofi Pasteur – Forecast for Influenza Vaccine Net Sales (Million US$),2016 – 2022
Figure 10 3: GSK – Influenza Vaccine Net Sales (Million US$),2011 – 2015
Figure 10 4: GSK – Forecast for Influenza Vaccine Net Sales (Million US$),2016 – 2022
Figure 10 5: AstraZeneca – Influenza Vaccine Net Sales (Million US$),2011 – 2015
